Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 主要终点
- Recurrence-free survival
研究概览
简要总结
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
详细描述
The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •patients diagnosed with FIGO stage II ovarian carcinoma;
- •cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed;
- •medical records maintain comprehensive data on treatment and follow-up;
- •no history of previous malignancies.
排除标准
- •neoadjuvant chemotherapy applied;
- •less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed;
- •medical records maintain incomplete data on treatment or follow-up;
- •history of previous malignancy.
研究组 & 干预措施
RFA alone
Patients undergo radiofrequency ablation alone.
RFA+CIK
Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
干预措施: Radiofrequency ablation (Procedure)
RFA+CIK
Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
干预措施: Cytokine-induced killer cells (Biological)
结局指标
主要结局
Recurrence-free survival
时间窗: 1 year
Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
次要结局
- Adverse events(4 weeks)